NASDAQ
60.27USD
-0.69 (-1.13%)
We have scored 18 news catalysts on Royalty Pharma plc (RPRX) over the past 12 months. The biggest single-day move next to one of them came Apr 16, 2026, when RPRX closed −0.5%: “Industrials Drive Gains for OUSM Small-Cap ETF”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
26.8B
P/E
—
EPS
—
Beta
0.41
52W range
35.915-64.38
Day range
60.04–61.12
Open
60.65
Prev close
60.96
Volume
2.8M
Avg volume
3.1M
Dividend
0.93
IPO
2020-06-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Royalty Pharma plc — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Royalty Pharma plc, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for RPRX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
